留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

抗肿瘤坏死因子α单克隆抗体治疗炎症性肠病专家共识(2017)

中华医学会消化病学分会炎症性肠病学组

中华医学会消化病学分会炎症性肠病学组. 抗肿瘤坏死因子α单克隆抗体治疗炎症性肠病专家共识(2017)[J]. 协和医学杂志, 2017, 8(4-5): 239-243. doi: 10.3969/j.issn.1674-9081.2017.05.009
引用本文: 中华医学会消化病学分会炎症性肠病学组. 抗肿瘤坏死因子α单克隆抗体治疗炎症性肠病专家共识(2017)[J]. 协和医学杂志, 2017, 8(4-5): 239-243. doi: 10.3969/j.issn.1674-9081.2017.05.009

抗肿瘤坏死因子α单克隆抗体治疗炎症性肠病专家共识(2017)

doi: 10.3969/j.issn.1674-9081.2017.05.009
基金项目: 

卫生部行业专项基金 201002020

详细信息
    通讯作者:

    钱家鸣  电话:010-69155019,E-mail:qianjiaming1957@126.com

  • 中图分类号: R574.1

  • [1] 中华医学会消化病学分会炎症性肠病学组.英夫利西治疗克罗恩病的推荐方案(2011年)[J].中华消化杂志,2011,31:822-824. doi:  10.3760/cma.j.issn.0254-1432.2011.12.008
    [2] Gomollon F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016:Part 1:Diagnosis and Medical Management[J]. J Crohns Colitis, 2017,11:3-25. doi:  10.1093/ecco-jcc/jjw168
    [3] Torres J, Caprioli F, Katsanos KH, et al. Predicting outcomes to optimize disease management in inflammatory bowel diseases[J]. J Crohns Colitis,2016,10:1385-1394. doi:  10.1093/ecco-jcc/jjw116
    [4] 李玥,舒慧君,吕红,等. 抗肿瘤坏死因子α治疗克罗恩病达深度缓解的临床预测因素[J]. 中华消化杂志, 2016,36:461-465. doi:  10.3760/cma.j.issn.0254-1432.2016.07.010
    [5] Harbord M, Annese V, Vavricka SR, et al. The first european evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease[J]. J Crohns Colitis, 2016,10:239-254. doi:  10.1093/ecco-jcc/jjv213
    [6] Gionchetti P, Dignass A, Danese S, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016:Part 2:Surgical Management and Special Situations[J]. J Crohns Colitis, 2017,11:135-149. doi:  10.1093/ecco-jcc/jjw169
    [7] 叶玲娜,夏菁菁,曹倩. 英夫利西治疗62例克罗恩病疗效观察[J]. 中华消化杂志, 2013,33:835-839. doi:  10.3760/cma.j.issn.0254-1432.2013.12.012
    [8] 陈白莉,陈旻湖,高翔,等. 新型生物制剂英夫利西治疗克罗恩病10例[J]. 中华消化杂志,2008,28:831-834. doi:  10.3760/j.issn:0254-1432.2008.12.014
    [9] Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease[J]. J Crohns Colitis, 2014,8:443-468. doi:  10.1016/j.crohns.2013.12.013
    [10] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志, 2015,31:1941-1960. doi:  10.3969/j.issn.1001-5256.2015.12.002
    [11] Ding NS, Hart A, De Cruz P. Systematic review:predicting and optimising response to anti-TNF therapy in Crohn's disease-algorithm for practical management[J]. Aliment Pharmacol Ther, 2016,43:30-51. doi:  10.1111/apt.13445
    [12] D'Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization:when to start, when to stop, which drug to choose, and how to predict response?[J]. Am J Gastroenterol, 2011,106:199-213. doi:  10.1038/ajg.2010.392
    [13] Nguyen GC, Seow CH, Maxwell C, et al. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy[J]. Gastroenterology, 2016,150:734-757. doi:  10.1053/j.gastro.2015.12.003
    [14] 上海市医学会儿科专业委员会免疫学组, 上海市免疫学会儿科临床免疫专业委员会, 上海市预防医学会免疫规划专业委员会. 免疫异常儿童疫苗接种(上海)专家共识[J]. 临床儿科杂志, 2014,32:1181-1190. doi:  10.3969/j.issn.1000-3606.2014.12.021
  • 加载中
计量
  • 文章访问数:  67
  • HTML全文浏览量:  4
  • PDF下载量:  27
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-05-23
  • 刊出日期:  2017-09-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!